Oophorectomy, Estrogen Therapy and Cardiovascular Disease Risk in Young Women

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-15

Study Completion Date

2023-08-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Researchers are trying to assess the appropriate dose of estrogen for decreasing the risk of cardiovascular disease in women who have removal of their ovaries at a young age, before the age of 46 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Estrogen, HDL, and Coronary Heart Disease in Women

NCT00083824

Cardiovascular Diseases Coronary Disease Heart Diseases +1 more

COMPLETED PHASE2/PHASE3

Impact of Estradiol on Endothelial Function in Peri-Menopausal Women

NCT04255160

Perimenopause Vasodilation Estrogen

RECRUITING PHASE4

Effects of Estrogen on Heart Health in Women With Primary Ovarian Insufficiency

NCT06866119

Primary Ovarian Insufficiency Premature Menopause Metabolic Complications +2 more

NOT_YET_RECRUITING

Estrogen Replacement to Reduce Risk of Neurologic Injury After Coronary Artery Bypass Graft Surgery

NCT00123539

Coronary Disease Cardiovascular Diseases Heart Diseases +1 more

TERMINATED NA

Midlife Cholesterol Study

NCT00361075

Menopause Postmenopause Premenopause +1 more

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Baseline Study Visit: Subjects will report for the Baseline Study Day in an 8 hour fasting state (water only) and refrain from heavy exercise, caffeine, and alcohol for 24 hours. The participant will undergo study specific procedures including a urine pregnancy test if they are of child bearing potential. Participants will also complete a set of questionnaires. After the completion of the study tests, participants will be offered a meal.

Participants scheduled for surgery to remove their ovaries: after the surgery subjects will be randomized to one of two groups. They will receive the standard dose of the hormone (estrogen) patch, generally prescribed to patients after removal both ovaries. Or sent home on the standard dose hormone patch, hormone levels will be tested every 3-4 weeks, and patch dose adjusted until the estrogen level is reached that results in the hormone levels of a young woman before menopause. In order to check hormones, subjects will be able to choose to have a lab kit sent to them and have the draw done locally, or can come in person.

Participants will also receive a second hormone prescription if they have an intact uterus to protect the lining of the uterus from the effects of using estrogen alone.

6-Month Study Visit: Subjects will be asked to come back and repeat most of the study specific tests from the baseline study visit that will take about 5 hours.

1-Year Study Visit: Subjects will be asked to come back for the final visit and will repeat all the study tests done at baseline visit. This visit will take about 5 hours.

Control Group: Healthy subjects serving as controls to see how measures change over time will not undergo a surgery or be given estrogen. These healthy subjects will return after the baseline visit to repeat study visits at 6 and 12-months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Risk Reduction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Subject be placed into three different study arms. Subjects undergoing surgery will be randomized to receive either standard hormone therapy or individualized hormone therapy. These arms will be compared against each other as well as a third arm of healthy timed-control subjects

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard replacement therapy regimen

100 mcg transdermal estradiol patch (or equivalent oral dose)

Group Type ACTIVE_COMPARATOR

Estradiol 100 Micrograms Patch

Intervention Type DRUG

Standard

Titrated replacement therapy regimen

Transdermal estradiol patch (or equivalent oral dose) titrated to achieve pre-menopausal estradiol level

Group Type ACTIVE_COMPARATOR

Estradiol Patch

Intervention Type DRUG

Individualized

Timed Control Group

Healthy age-matched subjects not on hormone therapy

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Estradiol 100 Micrograms Patch

Standard

Intervention Type DRUG

Estradiol Patch

Individualized

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Premenopausal women undergoing (or completion of a) bilateral oophorectomy for non-malignant diagnoses at Mayo Clinic, Rochester; or premenopausal women not undergoing the procedure for the timed control group
* Currently between the ages of 21- 45 years
* Able to participate fully in all aspects of the study
* Able to understand and sign the informed consent.

Exclusion Criteria

* History of hepatic, renal, or hematological diseases
* History of venous thromboembolism; peripheral vascular disease; coronary artery disease; stroke/neurovascular disease
* Chemotherapy or radiation therapy in the preceding 3 months
* Current tobacco use
* Current use of medication that alters autonomic or vascular function (e.g. tricyclic antidepressants, α-blockers, β-blockers, etc.) or aromatase inhibitor/tamoxifen therapy
* Contra-indication to estrogen use
* Current or previous diagnosis of breast and endometrial cancer
* For Timed Controls: Are currently pregnant or lactating, or are of child-bearing potential or are likely to become pregnant during the study and unwilling to use contraception; Acceptable forms include:Barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm), Copper Intra Uterine Device, Hysterectomy, Tubal ligation, Abstinence (no sex)
* Any condition or factor judged by the investigator to preclude participation in the study

Minimum Eligible Age

21 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes